| Acquired by | Ligand Pharmaceuticals |
| Price | $72.5M |
| Date | 9/08 |
| Website | pharmacopeia.com |
| Category | BioTech |
| Phone | 609-452-3600 |
| Employees | 169 |
| Founded | 1993 |
| TOTAL | $7.63M |
| VENTURE FUNDING TOTAL | $7.63M |
| Venture Round, 7/05 Rima Management Iroquois Capital Downsview Capital Clarion Capital Fifth Third Asset Management Nite Capital Management Crestview Capital Highbridge Capital Management Balyasny Asset Management Carpe Diem Capital Management | $7.63M |
Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renal diseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company’s products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc.
